Clinical Scorecard: New Medications for Dry Eye and Presbyopia
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease and Presbyopia |
| Key Mechanisms | Topical prescription therapies targeting TRPM8 receptors and cholinergic pathways. |
| Target Population | Adults aged 30 years and older, including post-LASIK patients and pseudophakes. |
| Care Setting | Ophthalmology clinics and outpatient settings. |
Key Highlights
- Pilocarpine 0.4% shows significant improvement in near visual acuity.
- Aceclidine 1.44% has rapid onset and high selectivity for iris sphincter activity.
- Acoltremon 0.003% effectively stimulates tear production in dry eye patients.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and perform ocular surface evaluations.
Management
- Consider pilocarpine, aceclidine, or acoltremon based on patient needs.
Monitoring & Follow-up
- Monitor for adverse events and visual acuity improvements.
Risks
- Classwide warnings include blurred vision and caution with night driving.
Patient & Prescribing Data
Adults with presbyopia and dry eye disease.
Topical miotics are approved for all adults, including those with inadequate response to other treatments.
Clinical Best Practices
- Remove contact lenses before instillation and wait 10 minutes before reinsertion.
- Conduct retinal examination prior to initiating miotic therapies.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
